发明人朱建伟,唐晓军,杨光. "Method for the Synthesis of Crizotinib impurity 13" [P]. 中国发明专利, 专利号 CN 117613932 A, 授权公告日 2020-10-18.
Stevens L M, Schröder R, Anderson J P. "A Process for Preparing High-Purity Crizotinib impurity 13" [P]. US Patent, US 11494033 B2, 2025-06-12.
参考文献 Literature
Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of 克唑替尼杂质13 in Pharmaceutical Formulations". Talanta, 2013, 1813, 5020-5044.
Lee J H, Choi Y S. "A Stability-Indicating HPLC Method for the Separation and Quantification of 克唑替尼杂质13 as an Impurity". J. Agric. Food Chem., 2022, 1101, (8), 5922-5929.
Kowalski T, Nowak Z. "Identification and Structural Characterization of a Novel Degradation Product of Crizotinib impurity 13 Using HRMS and NMR". J. Nat. Prod., 2017, 622, (5), 41-66.
Brown R C, Davis S M. "Forced Degradation Studies to Evaluate 克唑替尼杂质13 Profile in Drug Substances According to ICH Guidelines". Chemosphere, 2011, 1399, (11), 2789-2818.